alexa Erythroderma Due to the Association of Pegylated Interferon Alpha-2a and Ribavirin | Open Access Journals
ISSN: 2167-0870
Journal of Clinical Trials
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Erythroderma Due to the Association of Pegylated Interferon Alpha-2a and Ribavirin

Askour Majda1*, Bounniyt Hafsae1, Jaiteh Lamin2, Badrane Narjis3, Senouci Karima1 and Hassam Badredine1

1Department of Dermatology-Venereology, Ibn Sina University Hospital, Mohammed V University, Rabat, Morocco

2Department of General Surgery A, Ibn Sina University Hospital, Mohammed V University, Rabat, Morocco

3Poison Control and Pharmacovigilance Centre of Morocco, Rabat, Morocco

*Corresponding Author:
Askour Majda
Department of Dermatology-Venereology, Ibn Sina University Hospital
Mohammed V University, Rabat, Morocco
Tel: +212-668-69-01-03
E-mail: [email protected]

Received date: January 11, 2017; Accepted date: March 29, 2017; Published date: April 07, 2017

Citation: Majda A, Hafsae B, Lamin J, Narjis B, Karima S, et al. (2017) Erythroderma Due to the Association of Pegylated Interferon Alpha-2a and Ribavirin. J Clin Trials 7:304. doi:10.4172/2167-0870.1000304

Copyright: © 2017 Majda A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Clinical Trials


The dermatological adverse effects due to the association of interferon Alpha and ribavirin in patients treated for hepatitis C are becoming more frequent but little is known about them. Such adverse effects range from eczema to the onset or the exacerbation of a pre-existing autoimmune disease. This may influence the therapeutic management of such patients.


Erythroderma; Hepatitis C; Interferon alpha 2a; Ribavirin


Several cutaneous adverse effects have been described following the use of interferon (IFN) alpha 2a combined with Ribavirin in patients treated for hepatitis C. We report a case of erythroderma that has never been previously described in the literature.

Clinical Case

A 73-year-old man with a history of Hepatitis C for the past two years received 6 months of treatment with a combination of ribavirin capsules, 600 mg orally twice daily, and recombinant PEGylated interferon (PegINF) alpha-2a at a dose of 180 μg once weekly in subcutaneous injection. A week before completing his treatment, the patient noticed generalized pruritus associated with skin infiltrations. Clinically, dry pruritic erythroderma with digitiform infiltrated areas on the skin of the back and wrists were observed as well as infiltration of the scalp giving a cerebriform appearance (Figures 1 and 2).


Figure 1: Dry pruritic erythroderma.


Figure 2: Scratching lesions in the right arm, on an erythematosquamous skin.

Further examination found skin cracks on the hand and feet with an erosive cheilitis (Figure 3). The rest of the physical examination was noticeable for bilateral axillary lymphadenopathies. The lab studies were remarkable for an inflammatory anaemia with eosinophilia at 1700 elements/IU, lymphopenia at 920 elements/IU, Gamma-glutamyl– transferase at twice normal levels and hypoalbuminemia at 30 g/L. At the cutaneous biopsy, apoptotic bodies were found at the level of the epidermis.


Figure 3: Dry Erythroderma with cracks in the feet.

The underlying dermis harbored a perivascular inflammatory infiltrate composed of lymphocytes, histiocytes and polynuclear cells, which were essentially eosinophilic. Lymphocyte exocytosis was noted, we concluded to an allergic reaction. With clinical improvement of the patient under symptomatic treatment and the negative results of the biopsy in search of a cutaneous lymphoma, we retained the diagnosis of drug induced eruptions in response to the association of interferon alfa and ribavirin.


The cutaneous adverse effects of IFN occur frequently and are well known. They occur regardless of the disease being treated. The recent availability of new forms of late acting IFN (PEGylated interferon or PegIFN) and their combination with new molecules particularly ribavirin for the treatment of hepatitis contributes to the emergence or modification of cutaneous adverse effects [1,2]. Such effects may include dry skin, eczema, adverse effects on the hair and nails (telogen effluvium, abnormal coloration, hypertrichosis), vascular events (acrocyanosis, livedo, Raynaud's syndrome, necrosis of the extremities), the appearance or worsening of certain immune dysfunction skin diseases (vitiligo, lichen, psoriasis, lupus, autoimmune bullous diseases) and lesions of cutaneous and visceral sarcoidosis [3-5]. These adverse effects decrease with lowering doses of interferon or when it is discontinued as was the case in our patient. Two months after discontinuation of the suspected drug agent the association of PegINF alpha-2a with ribavirin, we observed marked clinical improvement in our patient who was put on supportive treatment based on an emollient and antihistamines.


In presenting this case, we hope to create awareness for those who prescribe these drug agents. Particular emphasis is put on the association of PEGylated IFN-Ribavirin in the treatment of patients with Hepatitis C with its potentially debilitating side effects on such patients.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 358
  • [From(publication date):
    March-2017 - Sep 22, 2017]
  • Breakdown by view type
  • HTML page views : 320
  • PDF downloads :38

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquav[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version